Drugmaker Hindustan Laboratories files IPO papers with Sebi to fund working capital

Generic drug maker Hindustan Laboratories has filed preliminary papers with capital markets regulator SEBI to raise funds through an initial public offering (IPO) to meet the company's working capital requirements.

The offer is a mix of fresh issue of 50 lakh shares and an offer-for-sale (OFS) of 91 lakh shares by the promoter, according to the draft red herring prospectus (DRHP).

The company proposes to utilise IPO proceeds for funding working capital requirements and general corporate purposes. 

Also Read: Chevron shares rally 10% in premarket trading after Trump's Venezuela remark 

Headquartered in Mumbai, Hindustan Laboratories is a pharmaceutical company that largely operates under a business-to-government (B2G) framework to manufacture and supply generic medicines to government institutions.

It produces a wide variety of therapeutic formulations in several forms, including tablets, capsules, liquid orals, ointments, and powders, among others.

The company has so far supplied products across India to 27 states and Union Territories during the six months ended September 30, 2025.

Choice Capital Advisors has been appointed as the book-running lead manager to the issue

Also Read: L&T Finance Q3 retail disbursements up 49% YoY, loan book jumps 20%